

# Asia-Pacific Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

<https://marketpublishers.com/r/A7D126AF75AEN.html>

Date: March 2018

Pages: 388

Price: US\$ 2,500.00 (Single User License)

ID: A7D126AF75AEN

## Abstracts

Asia-Pacific injectable drug delivery market is expected to reach USD 220,922.25 million by 2025 from USD 67,319.56 million in 2017, at a CAGR of 13.9% in the forecast period 2018 to 2025.

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for Asia-Pacific injectable drug delivery market are listed below:

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

The market is further segmented into:

Type

Usage Pattern

End-User

Mode of Administration

Distribution Channel

Application

Geography

The Asia-Pacific injectable drug delivery market is segmented on the basis of type, portability, type, product type, and application, and usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The Asia-Pacific injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with

80.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 178,225.1 million by 2025.

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 49.4% market share in 2018, growing at a CAGR of 13.7% and will cross USD 107,631.3 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 15.0% in the forecast period, and is expected to reach USD 51,374.1 million in 2025 from USD 14,319.8 million in 2017

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 94.2% market share in 2018, growing at a CAGR of 13.9% and will cross USD 209,048.6 million by 2025.

On the basis of mode of administration, the market is segmented into skin, circulatory/musculoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 50.4% market share in 2018, growing at a CAGR of 14.2% and will cross USD 113,780.0 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 58.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 129,566.3 million by 2025. However, home healthcare settings segment is expected to grow at the highest CAGR of 15.2% in the forecast period, and is expected to reach USD 44,906.7 million in 2025 from USD 12,286.6 million in 2017

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 75.5% market share in 2018, growing at a CAGR of 14.2% and will cross USD 170,166.5 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 14.9% in the forecast period, and is expected to reach USD 28,274.5 million in 2025 from USD 7,975.8 million

in 2017.

Based on geography, the Asia-Pacific injectable drug delivery market is segmented into geographical regions, such as,

Japan

China

India

South Korea

Australia

Thailand

Malaysia

Singapore

Indonesia

Taiwan

Rest of APAC

Covered in this report

The report covers the present scenario and the growth prospects of the Asia-Pacific injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

## Contents

### 1 INTRODUCTION

- 1.1 Overview Of Asia-Pacific Injectable Drug Delivery Market
- 1.2 Currency And Pricing
- 1.3 Limitation
- 1.4 Markets Covered

### 2 MARKET SEGMENTATION

- 2.1 Markets Covered
- 2.2 Geographic Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Research Methodology
- 2.6 Primary Interviews With Key Opinion Leaders
- 2.7 Secondary Sources
- 2.8 Assumptions

### 3 MARKET OVERVIEW

- 3.1 Drivers
  - 3.1.1 Rising Cases Of Chronic Diseases
  - 3.1.2 Rising Demand Of Self-Injection Devices
  - 3.1.3 Growth Of Biologics Market
  - 3.1.4 Technological Advancements And Innovations In Drug Delivery Market
- 3.2 Restraints
  - 3.2.1 Needlestick Injuries And Infections
  - 3.2.2 High Cost Of Development
  - 3.2.3 Strict Regulatory Framework
- 3.3 Opportunity
  - 3.3.1 Increasing Demand For Generic And Biosimilar Drugs
    - 3.3.1.1 Generics
    - 3.3.1.2 Biosimilars
  - 3.3.2 Increasing Demand For Contraceptive Injectables
  - 3.3.3 Increasing Demand For Self-Administration Of Drugs
- 3.4 Challenges
  - 3.4.1 Alternative Route Of Drug Administration

- 3.4.2 Product Recall
- 3.4.3 Stability Of Products
- 3.4.4 Sterility Of Injections

## **4 EXECUTIVE SUMMARY**

## **5 PREMIUM INSIGHTS**

## **6 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY TYPE**

- 6.1 Overview
- 6.2 Injectable Drug Delivery Devices
  - 6.2.1 Conventional Injection Devices
    - 6.2.1.1 Conventional Injection Devices, By Material
      - 6.2.1.1.1 Glass
      - 6.2.1.1.2 Plastic
    - 6.2.1.2 Conventional Injection Devices, By Product
      - 6.2.1.2.1 Fillable Syringes
      - 6.2.1.2.2 Prefilled Syringes
    - 6.2.1.3 Conventional Injection Devices, By Usability
      - 6.2.1.3.1 Reusable Syringes
      - 6.2.1.3.2 Disposable Syringes
  - 6.2.2 Self Injection Devices
    - 6.2.2.1 Needle Free Injectors (Nfi)
    - 6.2.2.2 Needle Free Injectors, By Product
      - 6.2.2.2.1 Fillable Needle-Free Injectors
      - 6.2.2.2.2 Prefilled Needle-Free Injectors
    - 6.2.2.3 Needle Free Injectors, By Technology
      - 6.2.2.3.1 Jet Based Needle Free Injectors:
      - 6.2.2.3.2 Spring Based Needle Free Injectors:
      - 6.2.2.3.3 Laser Based Needle Free Injectors:
      - 6.2.2.3.4 Vibration Based Needle Free Injectors:
    - 6.2.2.4 Needle Free Injectors, By Usability
      - 6.2.2.4.1 Reusable Needle-Free Injectors
      - 6.2.2.4.2 Disposable Needle-Free Injectors
    - 6.2.2.5 Auto Injectors
    - 6.2.2.6 Auto Injectors, By Product
      - 6.2.2.6.1 Fillable Auto Injectors
      - 6.2.2.6.2 Pre-Filled Autoinjectors

- 6.2.2.7 Auto Injectors, By Technology
  - 6.2.2.7.1 Automated Auto Injectors
  - 6.2.2.7.2 Manual Auto Injectors
- 6.2.2.8 Auto Injectors, By Design
  - 6.2.2.8.1 Standardized Auto Injectors
  - 6.2.2.8.2 Automated Autoinjectors
- 6.2.2.9 Auto Injectors, By Usability
  - 6.2.2.9.1 Reusable Autoinjectors
  - 6.2.2.9.2 Disposable Autoinjectors
- 6.2.2.10 Pen Injectors
- 6.2.2.11 Pen Injectors, By Product
  - 6.2.2.11.1 Single Chambered Pen Injectors
  - 6.2.2.11.2 Dual Chambered Pen Injectors
- 6.2.2.12 Pen Injectors, By Design
  - 6.2.2.12.1 Standard Pen Injectors
  - 6.2.2.12.2 Customized Pen Injectors
- 6.2.2.13 Pen Injectors, By Usability
  - 6.2.2.13.1 Reusable Pen Injectors
  - 6.2.2.13.2 Disposable Pen Injectors
- 6.2.2.14 Wearable Injectors
  - 6.2.2.14.1 Other Devices
- 6.3 Injectable Drug Delivery Formulation
  - 6.3.1 Conventional Drug Delivery Formulations
    - 6.3.1.1 Solutions
    - 6.3.1.2 Reconstituted/Lyophilized Formulations
    - 6.3.1.3 Suspensions
    - 6.3.1.4 Emulsions
  - 6.3.2 Novel Drug Delivery Formulations
    - 6.3.2.1 Colloidal Dispersions
      - 6.3.2.1.1 Niosomes
      - 6.3.2.1.2 Liposomes
      - 6.3.2.1.3 Polymeric Mixed Micelles
      - 6.3.2.1.4 Nanoparticles
      - 6.3.2.1.5 Nanosuspensions
      - 6.3.2.1.6 Nanoemulsions/Microemulsions
      - 6.3.2.1.7 Solid Lipid Nanoparticles
    - 6.3.2.2 Microparticles
      - 6.3.2.2.1 Microspheres
      - 6.3.2.2.2 Microcapsules

### 6.3.2.3 Long Acting Injection Formulation

## **7 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION**

### 7.1 Overview

### 7.2 Asia-Pacific Injectable Drug Delivery Market, By Application

### 7.3 Hormonal Disorders

#### 7.3.1 Injectable Drugs For Diabetes

#### 7.3.2 Injectable Drugs For Anemia

#### 7.3.3 Injectable Drugs For Reproductive Health Disease

#### 7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy

#### 7.3.5 Injectable Drugs For Osteoporosis

#### 7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd)

### 7.4 Oncology

### 7.5 Autoimmune Diseases

#### 7.5.1 Injectable Drugs For Rheumatoid Arthritis

#### 7.5.2 Injectable Drugs For Multiple Sclerosis

#### 7.5.3 Injectable Drugs For Crohn'S Diseases

#### 7.5.4 Injectable Drugs For Psoriasis

#### 7.5.5 Injectable Drugs For Other Autoimmune Diseases

### 7.6 Orphan Disease

### 7.7 Other Applications

#### 7.7.1 Injectable Drugs For Pain Management

#### 7.7.2 Injectable Drugs For Allergy Treatment

#### 7.7.3 Injectable Drugs For Aesthetic Treatments

#### 7.7.4 Injectable Drugs For Hepatitis C

#### 7.7.5 Injectable Drugs For Hemophilia

## **8 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN**

### 8.1 Overview

### 8.2 Curative Care

### 8.3 Immunizations

### 8.4 Other Usage Pattern

## **9 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION**

### 9.1 Overview



- 9.2 Skin
- 9.3 Circulatory/ Muskoskeletal
- 9.4 Organs
- 9.5 Central Nervous System

## **10 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY END USER**

- 10.1 Overview
- 10.2 Hospitals And Clinics
- 10.3 Home Healthcare Settings
- 10.4 Research Laboratories
- 10.5 Pharmaceutical And Biotechnological Companies
- 10.6 Other End Users

## **11 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL**

- 11.1 Overview
  - 11.1.1 Hospital Pharmacy
  - 11.1.2 Pharmacy Stores
  - 11.1.3 Direct Tender
  - 11.1.4 Online Pharmacy

## **12 ASIA-PACIFIC INJECTABLE DRUG DILIVERY MARKET BY GEOGRAPHY**

- 12.1 Asia-Pacific
  - 12.1.1 Japan Injectable Drug Delivery Market
  - 12.1.2 China Injectable Drug Delivery Market
  - 12.1.3 India Injectable Drug Delivery Market
  - 12.1.4 South Korea Injectable Drug Delivery Market
  - 12.1.5 Australia Injectable Drug Delivery Market
  - 12.1.6 Thailand Injectable Drug Delivery Market
  - 12.1.7 Malaysia Injectable Drug Delivery Market
  - 12.1.8 Singapore Injectable Drug Delivery Market
  - 12.1.9 Indonesia Injectable Drug Delivery Market
  - 12.1.10 Phillippines Injectable Drug Delivery Market
  - 12.1.11 Rest Of Asia-Pacific Injectable Drug Delivery Market

## **13 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE**

## 13.1 Company Share Analysis: Asia-Pacific

### **14 COMPANY PROFILES**

#### 14.1 Becton, Dickinson And Company

##### 14.1.1 Company Overview

###### 14.1.1.1 Drivers Explained

###### 14.1.1.2 Weaknesses Explained

###### 14.1.1.3 Oppurtunities Explained

###### 14.1.1.4 Threats Explained

##### 14.1.2 Product Portfolio

##### 14.1.3 Recent Developments

#### 14.2 Pfizer

##### 14.2.1 Company Overview

###### 14.2.1.1 Drivers Explained

###### 14.2.1.2 Weaknesses Explained

###### 14.2.1.3 Oppurtunities Explained

###### 14.2.1.4 Threats Explained

##### 14.2.2 Product Portfolio

##### 14.2.3 Recent Developments

#### 14.3 Baxter International

##### 14.3.1 Company Overview

###### 14.3.1.1 Drivers Explained

###### 14.3.1.2 Weaknesses Explained

###### 14.3.1.3 Oppurtunities Explained

###### 14.3.1.4 Threats Explained

##### 14.3.2 Product Portfolio

##### 14.3.3 Recent Developments

#### 14.4 Gerresheimer Ag

##### 14.4.1 Company Overview

##### 14.4.2 Product Portfolio

##### 14.4.3 Recent Developments

#### 14.5 Schott Ag Inc.

##### 14.5.1 Company Overview

##### 14.5.2 Product Portfolio

##### 14.5.3 Recent Developments

#### 14.6 Alkermes Inc.

##### 14.6.1 Company Overview

- 14.6.2 Product Portfolio
- 14.6.3 Recent Developments
- 14.7 Antares Pharma
  - 14.7.1 Company Overview
  - 14.7.2 Product Portfolio
  - 14.7.3 Recent Developments
- 14.8 Bepak (Subsidiary Of Consort Medical Company)
  - 14.8.1 Company Overview
  - 14.8.2 Product Portfolio
  - 14.8.3 Recent Developments
- 14.9 Elcam Medical
  - 14.9.1 Company Overview
  - 14.9.2 Product Portfolio
  - 14.9.3 Recent Developments
- 14.10 Eli Lilly And Company
  - 14.10.1 Company Overview
    - 14.10.1.1 Drivers Explained
    - 14.10.1.2 Weaknesses Explained
    - 14.10.1.3 Oppurtunities Explained
    - 14.10.1.4 Threats Explained
  - 14.10.2 Product Portfolio
  - 14.10.3 Recent Developments
- 14.11 Haselmeier
  - 14.11.1 Company Overview
  - 14.11.2 Product Portfolio
  - 14.11.3 Recent Developments
- 14.12 Mylan N.V.
  - 14.12.1 Company Overview
  - 14.12.2 Product Portfolio
  - 14.12.3 Recent Developments
- 14.13 Novo Nordisk
  - 14.13.1 Company Overview
  - 14.13.2 Product Portfolio
  - 14.13.3 Recent Developments
- 14.14 Owen Mumford Ltd
  - 14.14.1 Company Overview
  - 14.14.2 Product Portfolio
  - 14.14.3 Recent Developments
- 14.15 Sandoz International Gmbh

- 14.15.1 Company Overview
- 14.15.2 Product Portfolio
- 14.15.3 Recent Developments
- 14.16 Sanofi
  - 14.16.1 Company Overview
  - 14.16.2 Product Portfolio
  - 14.16.3 Recent Developments
- 14.17 Terumo Corporation
  - 14.17.1 Company Overview
  - 14.17.2 Product Portfolio
  - 14.17.3 Recent Developments
- 14.18 Teva Pharmaceutical
  - 14.18.1 Company Overview
    - 14.18.1.1 Drivers Explained
    - 14.18.1.2 Weaknesses Explained
    - 14.18.1.3 Oppurtunities Explained
    - 14.18.1.4 Threats Explained
  - 14.18.2 Product Portfolio
  - 14.18.3 Recent Developments
- 14.19 West Pharmaceutical Services, Inc
  - 14.19.1 Company Overview
  - 14.19.2 Product Portfolio
  - 14.19.3 Recent Developments
- 14.20 Ypsomed Holding Ag
  - 14.20.1 Company Overview
  - 14.20.2 Product Portfolio
  - 14.20.3 Recent Developments

## **15 RELATED REPORTS**

## List Of Figures

### LIST OF FIGURES

Figure 1 Asia-Pacific Injectable Drug Delivery Market: Segmentation

Figure 2 Asia-Pacific Injectable Drug Delivery Market: Geographic Scope

Figure 3 Asia-Pacific Injectable Drug Delivery Market: Data Triangulation

Figure 4 Asia-Pacific Injectable Drug Delivery Market: Research Snapshot

Figure 5 Asia-Pacific Injectable Drug Delivery Market: Bottom Up Approach

Figure 6 Asia-Pacific Injectable Drug Delivery Market: Top Down Approach

Figure 7 Asia-Pacific Injectable Drug Delivery Market: Interview Demographics

Figure 8 Figure: Drivers, Restraints, Opportunities, And Challenges Of The Injectable Drug Delivery Market

Figure 9 Number Of Needlestick Injuries

Figure 10 Technological Development And Increasing Prevalence Of Chronic Diseases Are Expected To Drive The Market For Injectable Drug Delivery In The Forecast Period 2018 To 2025

Figure 11 Injectable Drug Delivery Formulation Market Segment Is Expected To Account For The Largest Share Of The Asia-Pacific Injectable Drug Delivery Market In 2018 & 2025

Figure 12 North America Is The Highest Growing And Most Profitable Revenue Pockets For Injectable Drug Delivery Manufacturers In The Forecast Period To 2025

Figure 13 Asia-Pacific Injectable Drug Delivery Market: By Type, Snapshot 2016

Figure 14 Asia-Pacific Injectable Drug Delivery Market: By Application, Snapshot 2017

Figure 15 Asia-Pacific Injectable Drug Delivery Market: By Usage Pattern, Snapshot 2017

Figure 16 Asia-Pacific Injectable Drug Delivery Market: By Mode Of Administration, Snapshot 2017

Figure 17 Asia-Pacific Injectable Drug Delivery Market Dominated By Hospital And Clinics Segment

Figure 18 Asia-Pacific Injectable Drug Deliverymarket: By End-User, Snapshot 2017

Figure 19 Asia-Pacific Injectable Drug Delivery Market: By Distribution Channel, Snapshot 2017

Figure 20 Asia-Pacific Injectable Drug Delivery Market Snapshot (2017)

Figure 21 Asia-Pacific Injectable Drug Delivery Market: Company Share 2017 (%)

Figure 22 Becton, Dickinson And Company: Swot (Strength, Weakness, Opportunities And Threats)

Figure 23 Becton, Dickinsom And Company: Revenue Analysis

Figure 24 Pfizer, Inc.: Swot (Strength, Weakness, Opportunities And Threats)

Figure 25 Pfizer, Inc.: Revenue Analysis

Figure 26 Baxter International Inc.: Swot (Strength, Weakness, Opportunities And Threats)

Figure 27 Baxter International, Inc.: Revenue Analysis

Figure 28 Gerresheimer Ag: Revenue Analysis

Figure 29 Schott Ag Inc.: Revenue Analysis

Figure 30 Alkermes Inc.: Revenue Analysis

Figure 31 Antares Pharma: Revenue Analysis

Figure 32 Bespak: Revenue Analysis

Figure 33 Elcam Medical: Revenue Analysis

Figure 34 Eli Lilly And Company: Swot (Strength, Weakness, Opportunities And Threats)

Figure 35 Eli Lilly And Company: Revenue Analysis

Figure 36 Haselmeier: Revenue Analysis

Figure 37 Mylan N.V.: Revenue Analysis

Figure 38 Novo Nordisk: Revenue Analysis

Figure 39 Owen Mumford Ltd: Revenue Analysis

Figure 40 Sandoz International Gmbh: Revenue Analysis

Figure 41 Sanofi: Revenue Analysis

Figure 42 Terumo Corporation: Revenue Analysis

Figure 43 Teva Pharmaceutical: Swot (Strength, Weakness, Opportunities And Threats)

Figure 44 Teva Pharmaceutical: Revenue Analysis

Figure 45 West Pharmaceutical Services, Inc: Revenue Analysis

Figure 46 Ypsomed Holding Ag: Revenue Analysis

## I would like to order

Product name: Asia-Pacific Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Product link: <https://marketpublishers.com/r/A7D126AF75AEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A7D126AF75AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

